Frost & Sullivan Selects Bone Solutions for Technology Leadership of the ...( Unique Platform in the Bone Graft Mar...),Health

Unique Platform in the Bone Graft Market

MOUNTAIN VIEW, Calif., June 22 /PRNewswire/ -- Based on its analysis of the bone graft market, Frost & Sullivan recognizes Bone Solutions, Inc. (BSI) with the North American Frost & Sullivan Award for Technology Leadership of the Year for its development of OsteoCrete(TM). The OsteoCrete(TM) is a revolutionary grafting material for attaching ligaments and tendons to bone and bone-to-bone. On May 21, 2009 OsteoCrete received FDA 510(k) clearance as a bone void filler for long bone and pelvis applications.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

OsteoCrete(TM) is composed of magnesium oxide (Mg), monopotassium phosphate, and a small component of tricalcium phosphate. This compound provides an osteoconductive, biologic scaffold onto which new bone can form during the window of healing. The Mg gives the cement a powerful binder quality that theoretically allows it to resist tensile forces at time zero, thereby potentially limiting graft-tunnel motion. Several in vivo animal and bench test studies have shown OsteoCrete(TM) to have a peak tensile load to failure that is up to three times higher that of calcium-based bone cements in both bone-bone and tendon-bone attachments.

"BSI's commercialization, following its FDA clearance, is the first solution under its magnesium technology platform for orthopedic surgeries and other orthobiologics applications," says Frost & Sullivan Research Analyst Aarti Shetty. "This disruptive adhesive technology has lucrative potential in human markets, as it potentially represents the first compound that can attach bone to bone, as well as ligaments and tendons to bone."

OsteoCrete(TM) makes use of this technology platform in humans as a bone void filler, and this platform could revolutionize sp
'/>"/>